TABLE 3.
Patient | Expression (%) of:
|
|||
---|---|---|---|---|
CD4+ CD25+ FOXP3+
|
CD4+ CD25+ FOXP3−
|
|||
E7 | L1 | E7 | L1 | |
Kcx19 | 24 | 22 | 37 | 36 |
Kcx21 | 9 | 9 | 15 | 18 |
a CD4+ T cells were tested as described in Materials and Methods after resting at least 10 days from last the restimulation. Differences in the no. of L1 CD4+ CD25+ FOXP3+ versus E7 CD4+ CD25+ FOXP3+ for both patients were not significant, while differences in the number of L1 CD4+ CD25+ FOXP3+ versus L1 CD4+ CD25+ FOXP3- and E7 CD4+ CD25+ FOXP3+ versus E7 CD4+ CD25+ FOXP3− for both patients were found to be significant at P > 0.01.